Company intelligence / Profile preview
Aptinyx Inc.
Evanston, Illinois, USaptinyx.com ↗
- Ownership
- Private
- Employees
- ~12
- Development stage
- Phase 2
01
Overview
Aptinyx has had several Phase 2 clinical trials with disappointing results. NYX-458 did not demonstrate sufficient efficacy in cognitive impairment associated with Parkinson's disease and dementia with Lewy bodies[9]. NYX-2925 did not achieve the primary endpoint in a Phase 2b study for fibromyalgia[10]. The company terminated its study of NYX-783 in PTSD to analyze available data[9].
- Therapeutic areas
- PsychiatryNeurologyRheumatology
- Modalities
- Small moleculessynthetic small molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Allergan plc
Beyond the preview
Go deeper on Aptinyx Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aptinyx Inc..